Table 1.
Patient’s lymphocyte phenotyping and T-lymphocytes proliferation in response to mitogens, performed by FACS at 5 months of life
| Cell population | % | Cells/μl |
|---|---|---|
| Lymphocytes | 7945 | |
| T-Lymphocytes | 75 | 7282 |
| CD3+CD4+ | 66 | 6369 |
| CD3+CD8+ | 9 | 881 |
| CD45+CD3+CD4+CD31+ | 24 | 1528 |
| CD45+CD3+CD4+CD45RO+ | 54 | 3439 |
| CD45+CD3+CD4+CD45RA+ | 46 | 2930 |
| CD45+CD3+CD4+CD45RA+CD31+ | 39 | 2485 |
| B-Lymphocytes | 5 | 481 |
| CD27+ | 2 | 10 |
| CD27+IgM+IgD+ | 76 | 9 |
| CD27+IgM−IgD− | 24 | 2 |
| CD3−CD16+CD56+ | 2 | 206 |
| CD3−CD19+CD40+ | 99 | 1906 |
| CD3+CD8−CD40L | 97 | 6175 |
| T-lymphocytes proliferation assay | ||
| CFSE+ w/o stimulus | 98% | |
| PHA (10 μM) | 77% | |
| Anti-CD3 antibody and IL-2 (30 U/ml) | 85% | |